CN101210232B - Mesenchyme stem cell preserving fluid - Google Patents
Mesenchyme stem cell preserving fluid Download PDFInfo
- Publication number
- CN101210232B CN101210232B CN2006101306382A CN200610130638A CN101210232B CN 101210232 B CN101210232 B CN 101210232B CN 2006101306382 A CN2006101306382 A CN 2006101306382A CN 200610130638 A CN200610130638 A CN 200610130638A CN 101210232 B CN101210232 B CN 101210232B
- Authority
- CN
- China
- Prior art keywords
- cell
- mesenchymal stem
- stem cells
- stem cell
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Abstract
The invention discloses a preservation solution for mesenchymal stem cells and application thereof. The cell preservation solution contains human albumin and heparin as the main components, and other auxiliary reagents such as human cytokine, phosphate ion, metal ions or monosaccharide are contained in a buffer solution for preserving human mesenchymal stem cells. The preservation solution can keep high survival rate of human mesenchymal stem cells in transportation process, reduce adhesion between cells and between the cell and the inner wall of a container, and reduce the possible occurrence of cell mass embolism in blood vessel while clinically infusing human mesenchymal stem cells. The mesenchymal stem cells can be maintained in a state of single-cell suspension at an environment temperature of 4 to 15 DEG C for 24 h, thus greatly enlarging the clinic application range of the human mesenchymal stem cells. The components used in the solution accord with the clinic application, and can meet the requirement for clinic use of the human mesenchymal stem cells.
Description
Technical field
The present invention relates to biological technical field, especially a kind of mesenchyme stem cell preserving fluid and uses thereof.
Background technology
Mescenchymal stem cell (mesenchymal stem cells; MSCs) be to derive to grow early stage mesoderm and ectodermic one type of multipotential stem cell; In marrow, find at first, receive people's attention day by day: 1) hematopoiesis support and short the implantation because of it has following characteristics.As the main cellular constituent of hematopoieticmicroenviron-ment---the ancestral cells of stromal cell lines, MSCs realizes the finely regulating to hematopoiesis, the growth of hematopoiesis support stem/progenitor cells through direct effect, secretory cell epimatrix and the various kinds of cell factor of cell pair cell.Can promote the implantation of hematopoietic stem/progenitor cells with the hemopoietic stem cell co-transplantation, for improving the umbilical cord blood transplantation success ratio, it is significant to widen the umbilical cord blood transplantation scope of application.2) immunoregulation.MSCs expresses the MHC-I quasi-molecule; Do not express CD80, CD86, collaborative stimulation molecule such as HLA-DR; Externally suppress mixed lymphocyte reacion; Inducing immune tolerance in the body for the graft versus host disease that causes behind prevention and the treatment recessive allele hematopoietic cell transplantation, induces the tolerance of organ transplantation immunity that application promise in clinical practice is arranged.3) gene therapy.Because MSCs amplification in vitro, multiplication capacity are strong, can be used as the stem cell platform of genetic manipulation, very tempting prospect is arranged in gene therapy.4) multidirectional differentiation potential.In vivo/can be divided into multiple histocytes such as fat, bone, cartilage, muscle, tendon, ligament, nerve, liver, cardiac muscle, endothelium under the outer specific inductive condition; Still have multidirectional differentiation potential after continuous passage cultivation and the freezing preservation, can be used as the ideal seed cell and be used for organizational project.
Mescenchymal stem cell MSCs is an attached cell, is prepared into suspension and is easy to assemble agglomerating later on, when doing experimentation on animals, is easy to take place the cell mass vascular embolization through blood infusion MSCs, causes the death of laboratory animal." primary mesenchymal stem cells " injection liquid phase clinical study that is used for leukemia treating of China's development at present.The umbilical cord mesenchyma stem cell of country's stem cell line systems engineering important component part is also set up in Tianjin.Mescenchymal stem cell acceleration from now on is trend of the times in clinical application, is very important so study a kind of effective mesenchyme stem cell preserving fluid.Can make present human mesenchymal stem cell can only be at home among a small circle application extension to the whole nation, and even surrounding countries.And can carry out at present that people MSCs separates and the unit of large scale culturing seldom; And horse back infusion after need finishing dealing with cell; In case after the placement several hrs; It is agglomerating a large amount of gatherings of MSCs to occur, brings danger for patient's infusion, makes the scope that can carry out the MSCs clinical application be very limited.It is agglomerating that present most laboratory generally uses diethylamine tetraacethyl (EDTA) to suppress the mescenchymal stem cell gathering; EDTA (clinical in claiming edetate) is a kind of sequestrant; Clinical disodium salt or calcium disodium salt with edetic acid, edetate has teratogenesis in experimentation on animals, though zinc can resist this effect; But what we preserved is mescenchymal stem cell, for caution's sake preferably without edetate.We find that heparin also can be used for suppressing mescenchymal stem cell and assemble agglomerating.Heparin is present clinical anticoagulant commonly used, and the heparin of clinical usefulness is generally heparinates such as heparin sodium, calciparine, Lithium heparinate, low molecular sodium heparin and low molecular heparin calcium.But Low molecular heparin and unfractionated heparin ratio have long half time, the advantage that biological activity is high, and hemorrhage side effect is few, can monitor coagulation indexes during with Low molecular heparin, relatively safety.The bioavailability of low molecular heparin calcium is high, and the anti thrombotic action time is 24h, and bleeding tendency is seldom arranged.So in experiment, selecting for use low molecular heparin calcium to suppress MSCs assembles agglomerating.
It is general with containing the high viability that serum keeps cell to preserve cell at present; But also be not fit to the human serum that clinical infusion uses at present, and serum composition is complicated, quality is unexpectedly controlled; Nutritive ingredient is more relatively, and the gathering that in the high viability that keeps cell, can increase MSCs is agglomerating.And the BSA of suitable concn also can keep the high viability of cell within a certain period of time.Clinical widely used albumin preparation is also arranged at present.In experiment and clinical application, also there is the people singly to use BSA to keep the high viability of cell.Up to the present find to have the people in mesenchyme stem cell preserving fluid, to use BSA and heparin simultaneously.
Summary of the invention
Technical problem to be solved by this invention is; A kind of mesenchyme stem cell preserving fluid and uses thereof is provided; Can make the maintenance high viability of human mesenchymal stem cell in transportation; Reduced between the cell and the sticking of cell and container inner wall, occurred the possibility of cell mass embolism when reducing clinical infusion human mesenchymal stem cell in the blood vessel.
In order to address the above problem, the technical scheme that the present invention adopts is: a kind of human mesenchymal stem cell is preserved liquid, comprises 0.01%-20% BSA, 1-5000AXaIU/ml heparin and solution medium.
Described BSA is the rHSA that clinical approval is used.
Said heparin is the heparinate that clinical approval is used.
Said heparinate is a kind of in low molecular heparin calcium or the low molecular sodium heparin.
Described solution medium is no bacterium, virus, mycoplasma contamination, the liquid medium of endotoxin content＜5EU/ml.
Described solution medium mainly contains serum free medium or the phosphate buffered saline buffer of saline water, TC199.
Aforesaid human mesenchymal stem cell is preserved liquid, is used to preserve the mescenchymal stem cell that the source comprises all or part of histoorgan of marrow, blood, fat, umbilical cord, placenta, amniotic fluid, skin, liver, muscle, blood vessel, nerve, lung, kidney, brain, miscarriage embryo/fetus.
Beneficial effect of the present invention: mesenchyme stem cell preserving fluid of the present invention; Contain human albumin and heparin as staple; Other auxiliary reagents such as human cytokine, phosphate anion, metals ion or monose etc. are included in the buffered soln that depositary's mescenchymal stem cell adopted together.Above-mentioned cell-preservation liquid can make the maintenance high viability of human mesenchymal stem cell in transportation, has reduced between the cell and the sticking of cell and container inner wall, and occurs the possibility of cell mass embolism when reducing clinical infusion human mesenchymal stem cell in the blood vessel.It is main state that cell-preservation liquid of the present invention can make mescenchymal stem cell in the time of envrionment temperature 4-15 ℃, in 24 hours, keep single cell suspension; The mescenchymal stem cell that this cell-preservation liquid is preserved can be sent to all parts of the country and surrounding countries through the modern transportation instrument; Increased the scope of clinical end user's mescenchymal stem cell greatly; Used composition is the composition that meets clinical use, can satisfy the needs of clinical end user's mescenchymal stem cell.
Description of drawings
Fig. 1 is the streaming result that the immunophenotype of umbilical cord mesenchymal stem cells is analyzed;
Fig. 2 is that artificial the setting judges that MSC assembles the standard of situation, is divided into level Four according to the weight of aggregation extent :+, ++, +++, ++ ++;
Fig. 3 respectively organized the gathering situation under the different preservation conditions after 24 hours; Be respectively the image of EDTA+1% BSA group, low molecular heparin calcium+1% BSA group and 1% BSA group aggregation extent from left to right.
Fig. 4 to be mescenchymal stem cell preserve in preserving liquid streaming result that immunophenotype is analyzed after 24 hours, on be 0 hour, is 24 hours down.
Embodiment
Below in conjunction with specific embodiment the present invention is further described.
Human mesenchymal stem cell of the present invention is preserved liquid, comprises 0.01%-20% BSA, 1-5000AXaIU/ml heparin and solution medium.Described BSA is the rHSA that clinical approval is used.
Said heparin is the heparinate that clinical approval is used.Said heparinate is a kind of in low molecular heparin calcium or the low molecular sodium heparin.Described solution medium is no bacterium, virus, mycoplasma contamination, the liquid medium of endotoxin content＜5EU/ml.Described solution medium mainly contains serum free medium or the phosphate buffered saline buffer of saline water, TC199.
Aforesaid human mesenchymal stem cell is preserved liquid, is used to preserve the mescenchymal stem cell that the source comprises all or part of histoorgan of marrow, blood, fat, umbilical cord, placenta, amniotic fluid, skin, liver, muscle, blood vessel, nerve, lung, kidney, brain, miscarriage embryo/fetus.
Solution medium in the mesenchyme stem cell preserving fluid can be used saline water, serum free medium etc.In experimenting, we find out that with mescenchymal stem cell at saline water; BSA; Preserve above 6 hours later survival rates in the preservation liquid that low molecular heparin calcium is configured to and be lower than serum free medium, the survival rate in the preservation liquid that BSA, low molecular heparin calcium are configured at TC199.And the solution medium of the medullary cell that is used for when at present the TC199 serum free medium often is used as clinical bone marrow transplantation suspending.So we select for use the TC199 serum free medium as the solution medium of preserving in the liquid.
Anticoagulin Xa iu/milliliter is expressed as AXaIU/ml.
Separation and the cultivation and the phenotypic evaluation of embodiment 1 people's umbilical cord cell
(1) external, people's umbilical cord is washed by phosphoric acid buffer (PBS) repeatedly, remove residual blood, shred to about 1mm
3Fritter, add the collagenase of raw material weight 0.1%, 37 ℃ of digestion 45 minutes; (2) add raw material weight 0.125% pancreatin (Sigma, USA) 37 ℃ of digestion is 45 minutes, in digestive process, stirs with rotor, adds the effect of an amount of serum termination pancreatin; (3) Digestive system is used screen filtration, successively uses 100 orders and 200 purpose strainer filterings, removes indigested tissue; (4) Digestive system after will filtering dilutes with phosphoric acid buffer, and Digestive system and phosphoric acid buffer liquid proportional are 1: 10 ratio; (5) centrifugal, obtain cell, the rotating speed of whizzer is the centrifugal 15min of 1500rpm/min, obtains cell; (6) cell is by 1～2 * 10
1/ cm
2Be inoculated in the plastic culture bottle, (Sigma, USA), (Gibco BRL, substratum USA) are put 37 ℃, 5%CO to 5% foetal calf serum (FCS) with containing the DMEM-LG/F12 substratum
2Incubator is cultivated, and changes liquid after 4-5 days, discards non-adherent cell, and half amount was changed liquid in later every 3-4 days.Treat that cell 80% merges, 0.25% trysinization was gone down to posterity by 1: 3.
The conventional digestion of attached cell back is with CD45, CD34, CD31 and the CD90 of FITC mark, the CD29 of PE mark, CD44, CD73, CD105, HLA-DR antibody and corresponding homotype contrasting marking cell thereof, flow cytometer (FACA Calibur type, USA) detection.Above FLA is all available from BD company (USA).
The streaming immunophenotype detected result of umbilical cord mesenchymal stem cells shows: umbilical cord mesenchymal stem cells high expression level CD90, CD29, CD44, CD73 and CD105, do not express CD45, CD34, CD31 and HLA-DR.(Fig. 1)
The solution medium that embodiment 2 preserves in the liquid and preparation method thereof is selected
1.1 operation steps
1.1.1 contain the TC199 and the preparation that contains 1% human serum albumin saline water of 1% human serum albumin.
1.1.2 with the TC199 that contains 1% human serum albumin with contain 1% human serum albumin saline water and prepare umbilical cord mesenchymal stem cells suspension, 5 * 10 respectively
5/ ml/ml.Packing 6 pipes (preserving 3 parallel pipes of liquid for every kind), the 2.5ml/ pipe.
1.1.3 the umbilical cord mesenchymal stem cells suspension is transferred to respectively in the cillin bottle, places 4 ℃, after the preservation in 8 hours, platform is expected blue dyeing counting cell survival rate.
The result judges: dead cell can be expected that orchid catches look by platform, the down visible navy blue cell of mirror, and viable cell is not colored, and is the water white transparency shape under the mirror.
The result:
| ? | The TC199 group | The saline water group |
| The counting cells number | 300 | 300 |
| Painted TCS | 19±2 | 167±16 |
| Cell survival rate % | 93.7±0.7 | 44.3±5.3 |
The selection of embodiment 3 human serum albumin concentration
1.1 operation steps
1.1.1 contain the preparation of 5%, 2%, 1% and 0.5% human serum albumin TC199.
1.1.2 preparation umbilical cord mesenchymal stem cells suspension, 5 * 10
5/ ml/ml.Packing 12 pipes (preserving 3 parallel pipes of liquid for every kind), the 2.5ml/ pipe.
1.1.3 800rpm, after 5min is centrifugal, supernatant discarded.Add the various preservation liquid that 2.5ml prepares respectively.
1.1.4 transfer to respectively behind the cell mixing in 12 cillin bottles, place 4 ℃, after the preservation in 8 hours, platform is expected blue dyeing counting cell survival rate.
The result judges: dead cell can be expected that orchid catches look by platform, the down visible navy blue cell of mirror, and viable cell is not colored, and is the water white transparency shape under the mirror.
The result:
1.1 operation steps
1.1.1 prepare respectively with the TC199 that contains 1% human serum albumin and to contain 0.01%EDTA, 75AXaIU/ml heparin sodium, the preservation liquid of 75AXaIU/ml low molecular heparin calcium.
1.1.2 preparation umbilical cord mesenchymal stem cells suspension, 5 * 10
5/ ml.Packing 9 pipes (preserving 3 parallel pipes of liquid for every kind), the 2.5ml/ pipe.
1.1.3 800rpm, after 5min is centrifugal, supernatant discarded.Add the various preservation liquid that 2.5ml prepares respectively.
1.1.4 transfer to respectively behind the cell mixing in 9 cillin bottles, respectively at 0 hour, 2 hours, 4 hours, 6 hours, 8 hours, the 24 hours time points of preserving, sampling and measuring cell survival rate.
1.1.5 the result judges: dead cell can be expected that orchid catches look by platform, the down visible navy blue cell of mirror, and viable cell is not colored, and is the water white transparency shape under the mirror.
The result:
| ? | 0.01％EDTA | The 75AXaIU/ml heparin sodium | The 75AXaIU/ml low |
| 0 |
100％ | 100％ | 100％ |
| 2 hours | 91.30％ | 93.30％ | 98.41％ |
| 4 hours | 84.57％ | 91.54％ | 97.65％ |
| 6 hours | 75.19％ | 87.36％ | 95.19％ |
| 8 hours | 69.67％ | 83.49％ | 94.3％ |
| 24 hours | 57.58％ | 74.71％ | 90.57％ |
Embodiment 5 EDTA, low molecular heparin calcium influences the umbilical cord mesenchymal stem cells accumulative
1.1 operation steps
1.1.1 prepare respectively with the TC199 that contains 1% human serum albumin and to contain 0.01%EDTA, the preservation liquid of 75AXaIU/ ml low molecular heparin calcium.
1.1.2 preparation umbilical cord mesenchymal stem cells suspension, 5 * 10
5/ ml.Packing 9 pipes (preserving 3 parallel pipes of liquid for every kind), the 2.5ml/ pipe.
1.1.3 800rpm, after 5min is centrifugal, supernatant discarded.Add the various preservation liquid that 2.5ml prepares respectively.
1.1.4 transfer to respectively behind the cell mixing in 6 cillin bottles, respectively at 0 hour, 2 hours, 4 hours, 6 hours, 8 hours, the 24 hours time points of preserving, microscope is according to the imaging down of 4 times of object lens.
1.1.5 the result judges: judge the gathering situation according to standard (Fig. 2).With set wherein a certain aggregation extent and just be corresponding+number number when suitable, as: ++; Being written as between certain two aggregation extent be last+and number number/back one added number, as :+/ ++.
Result: EDTA+1% BSA group: ++, low molecular heparin calcium+1% BSA group :-/+, 1% BSA group: +++/ ++ ++.(Fig. 3)
Embodiment 6 mescenchymal stem cells are preserved the analysis of immunophenotype after 24 hours in preserving liquid
Preserve cell at preservation liquid and get 1 * 10 respectively after 0 hour and 24 hours
6Individual cell, with the CD45 of the method indicia band FITC mark that the professional was familiar with, the CD73 of PE mark, CD105 and HLA-DR streaming antibody and corresponding homotype contrasting marking antibody thereof, (FACA Calibur type USA) detects flow cytometer.Above FLA is all available from BD company (USA).
Flow cytometer detects to be preserved before the liquid preservation respectively and the cellular immunization phenotype of preservation after 24 hours.Showed cell high expression level CD105, CD73 do not express hematopoietic cell phenotype HLA-DR, CD45 as a result, and immunophenotype does not have considerable change.Streaming figure sees (Fig. 4)
Embodiment 7 preservation liquid are used the effect with the mescenchymal stem cell that keeps derived from bone marrow
The mescenchymal stem cell of derived from bone marrow is digested, counts with the method that the professional knows, prepare mesenchymal stem cells MSCs suspension, 5 * 10 with the TC199 that contains 1% human serum albumin and 75AXaIU/ml low molecular heparin calcium
5/ ml.Transfer to respectively behind the cell mixing in 6 cillin bottles, respectively at 0 hour, 2 hours, 6 hours, 12 hours, 18 hours, the 24 hours time points of preserving, microscope is according to the imaging down of 4 times of object lens.Judge the gathering situation according to standard (Fig. 2).
The result:
| Time (hour) | 0 | 2 | 6 | 12 | 18 | 24 |
| State of aggregation | - | - | - | - | -/+ | -/+ |
The cell-preservation liquid of the present invention preparation can keep the mescenchymal stem cell in various sources, can make the maintenance high viability of mescenchymal stem cell in transportation, has reduced between the cell and the sticking of cell and container inner wall.Can satisfy the needs of clinical end user's mescenchymal stem cell, increase the scope of clinical end user's mescenchymal stem cell greatly.
Claims (4)
1. a human mesenchymal stem cell is preserved liquid; It is characterized in that; Comprise 0.01%-20% BSA, 1-5000AXaIU/ml heparin and solution medium; Described solution medium is the serum free medium of saline water, TC199 or in the phosphate buffered saline buffer any one, endotoxin content＜5EU/ml.
2. human mesenchymal stem cell according to claim 1 is preserved liquid, it is characterized in that, described BSA is the rHSA that clinical approval is used.
3. human mesenchymal stem cell according to claim 1 is preserved liquid, it is characterized in that, said heparin is the heparinate that clinical approval is used.
4. human mesenchymal stem cell according to claim 3 is preserved liquid, it is characterized in that, said heparinate is a kind of in low molecular heparin calcium or the low molecular sodium heparin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006101306382A CN101210232B (en) | 2006-12-28 | 2006-12-28 | Mesenchyme stem cell preserving fluid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006101306382A CN101210232B (en) | 2006-12-28 | 2006-12-28 | Mesenchyme stem cell preserving fluid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101210232A CN101210232A (en) | 2008-07-02 |
| CN101210232B true CN101210232B (en) | 2012-07-18 |
Family
ID=39610488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006101306382A Active CN101210232B (en) | 2006-12-28 | 2006-12-28 | Mesenchyme stem cell preserving fluid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101210232B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8969315B2 (en) | 2010-12-31 | 2015-03-03 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
| US9040035B2 (en) | 2011-06-01 | 2015-05-26 | Anthrogenesis Corporation | Treatment of pain using placental stem cells |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10104880B2 (en) | 2008-08-20 | 2018-10-23 | Celularity, Inc. | Cell composition and methods of making the same |
| CN101919380B (en) * | 2010-08-06 | 2014-10-22 | 青岛奥克生物开发有限公司 | Improved mesenchyme stem cell protection solution and application thereof |
| CN101971798A (en) * | 2010-11-03 | 2011-02-16 | 江苏省北科生物科技有限公司 | Human umbilical cord Wharton jelly tissue block freezing protection liquid |
| CN102008507B (en) * | 2010-11-21 | 2011-11-16 | 天津和泽干细胞科技有限公司 | Human umbilical cord mesenchymal stem cell (HUMSC) anti-hepatic fibrosis injection and preparation method thereof |
| CN102028970A (en) * | 2010-12-27 | 2011-04-27 | 协和干细胞基因工程有限公司 | Stem cell preparation for treating cirrhosis |
| WO2012112572A2 (en) * | 2011-02-18 | 2012-08-23 | Stemcyte, Inc. | Stem cells packaging and shipping |
| CN102228475A (en) * | 2011-06-09 | 2011-11-02 | 无锡人寰生物医药科技有限公司 | Stem cell compound medicament for preventing and/or treating cirrhosis and preparation method thereof |
| CN102948413B (en) * | 2011-08-29 | 2014-09-03 | 北京清美联创干细胞科技有限公司 | Hepatic stem cell preserving solution and applications of hepatic stem cell preserving solution |
| CN102365933B (en) * | 2011-10-24 | 2016-04-27 | 广州市天河诺亚生物工程有限公司 | A kind of mesenchyme stem cell preserving fluid and preparation method thereof and application |
| CN102433302B (en) * | 2011-12-15 | 2013-07-03 | 成都清科生物科技有限公司 | Serum-free culture medium for mesenchymal stem cells |
| CN102559581B (en) * | 2012-01-20 | 2014-09-10 | 四川大学华西医院 | Serum free hepatocyte medium |
| CN102719397B (en) * | 2012-07-16 | 2013-05-29 | 天津和泽干细胞科技有限公司 | Mesenchymal stem cell and application thereof in resisting HIV-1 (human immunodeficiency virus) |
| CN102807966B (en) * | 2012-08-16 | 2014-08-13 | 博雅干细胞科技有限公司 | Method for freezing and thawing placental whole cells and separating and expanding stem cells |
| CN103655614B (en) * | 2012-09-19 | 2019-06-28 | 西比曼生物科技（上海）有限公司 | The application in hepatitis is being prevented or treated to adipose tissue progenitor cell |
| CN102920735A (en) * | 2012-11-14 | 2013-02-13 | 青岛奥克生物开发有限公司 | Mesenchymal stem cell injection, preparation method and application thereof in preparing medicine for treating diabetes |
| CN103330720B (en) * | 2013-07-18 | 2014-10-01 | 广州市天河诺亚生物工程有限公司 | Mixing stem cell injection and preparation method thereof |
| CN104430301A (en) * | 2014-11-18 | 2015-03-25 | 成都康华生物制品有限公司 | Method for improving survival rate of human diploid cells |
| CN106031792A (en) * | 2015-03-10 | 2016-10-19 | 西比曼生物科技（上海）有限公司 | Composition for treating defects of articular cartilage |
| CN105076114A (en) * | 2015-08-21 | 2015-11-25 | 深圳爱生再生医学科技有限公司 | Serum-free preservation liquid for umbilical cord mesenchymal stem cells and application of serum-free preservation liquid |
| CN105052895B (en) * | 2015-09-01 | 2017-12-05 | 广州赛莱拉干细胞科技股份有限公司 | LAK cell preservation solution, preparation method thereof and LAK cell preservation method |
| CN105961374A (en) * | 2016-07-04 | 2016-09-28 | 深圳市合康生物科技股份有限公司 | Cell cryopreservation fluid |
| CN106665560B (en) * | 2017-01-16 | 2021-02-05 | 哈尔滨医科大学 | Immune cell frozen stock solution for direct venous return and application thereof |
| CN107410288B (en) * | 2017-08-26 | 2020-07-31 | 刘劼 | Storage liquid of human umbilical cord mesenchymal stem cells |
| CN109497038A (en) * | 2017-09-14 | 2019-03-22 | 青岛瑞思德生物科技有限公司 | A kind of fat saves liquid and preparation method thereof |
| CN107912420A (en) * | 2017-10-27 | 2018-04-17 | 北京协科医药科技有限公司 | A kind of cell preservation method, preserve liquid and preserve liquid and preparation method thereof |
| CN107912424A (en) * | 2017-12-01 | 2018-04-17 | 佛山科学技术学院 | A kind of special room-temperature extender of dog mescenchymal stem cell and application |
| CN108432742A (en) * | 2018-04-09 | 2018-08-24 | 佛山科学技术学院 | A kind of mescenchymal stem cell room temperature transport liquid |
| CN108753709A (en) * | 2018-06-21 | 2018-11-06 | 深圳至博生物科技有限公司 | A kind of serum free medium and its preparation and cell culture processes |
| CN108782544B (en) * | 2018-06-28 | 2021-01-01 | 吉林省拓华生物科技有限公司 | Cryopreservation solution and method for cryopreservation of large amount of mesenchymal stem cells |
| CN112167240A (en) * | 2019-07-02 | 2021-01-05 | 南京三生生物技术股份有限公司 | Clinical grade cell cold storage preservation solution and preparation method and application thereof |
| CN110551684B (en) * | 2019-09-16 | 2021-09-03 | 福建省海西细胞生物工程有限公司 | Preparation method of human umbilical cord mesenchymal stem cells |
| CN111011363B (en) * | 2019-12-16 | 2021-12-17 | 广东唯泰生物科技有限公司 | Mesenchymal stem cell cryopreservation liquid, cryopreservation method, preservation kit and recovery method |
| CN113577106A (en) * | 2020-04-30 | 2021-11-02 | 中国医学科学院北京协和医院 | Adipose-derived stem cell preparation and preparation method thereof |
| WO2021219003A1 (en) * | 2020-04-30 | 2021-11-04 | 中国医学科学院北京协和医院 | Adipose-derived stem cell preparation, preparation method therefor and use thereof |
| CN111849880B (en) * | 2020-06-23 | 2022-04-29 | 和携科技有限公司 | Recovery method of human adipose mesenchymal stem cells after ultralow-temperature cryopreservation |
| CN115039761A (en) * | 2022-06-20 | 2022-09-13 | 隆泰银信生物科技有限公司 | Mesenchymal stem cell preservation solution for clinical venous return or local injection and composition thereof |
| CN116569917B (en) * | 2023-07-13 | 2023-11-28 | 九天览月生物科技(天津)有限公司 | Cell, cell preservation solution, preservation method and application |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6743575B2 (en) * | 1996-06-14 | 2004-06-01 | Biostore New Zealand Ltd. | Compositions and methods for the preservation of living tissues |
| CN1786154A (en) * | 2005-10-18 | 2006-06-14 | 天津昂赛细胞基因工程有限公司 | Human placenta, umbilical cord mesenchyma stemcell stock and its construction method |
-
2006
- 2006-12-28 CN CN2006101306382A patent/CN101210232B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6743575B2 (en) * | 1996-06-14 | 2004-06-01 | Biostore New Zealand Ltd. | Compositions and methods for the preservation of living tissues |
| CN1786154A (en) * | 2005-10-18 | 2006-06-14 | 天津昂赛细胞基因工程有限公司 | Human placenta, umbilical cord mesenchyma stemcell stock and its construction method |
Non-Patent Citations (1)
| Title |
|---|
| 吴燕峰，等.联合低温保护剂对脐血造血干细胞长期低温保存的作用.《广东医学》.2001,第22卷(第8期),665－666. * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8969315B2 (en) | 2010-12-31 | 2015-03-03 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
| US9040035B2 (en) | 2011-06-01 | 2015-05-26 | Anthrogenesis Corporation | Treatment of pain using placental stem cells |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101210232A (en) | 2008-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101210232B (en) | Mesenchyme stem cell preserving fluid | |
| AU2008249204B2 (en) | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells | |
| US7311905B2 (en) | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells | |
| CN103583511B (en) | A kind of mesenchymal stem cell cryopreserving liquid and parenteral solution | |
| US20080118477A1 (en) | Umbilical cord mesenchymal stem cells support cord blood hematopoiesis | |
| TW200902718A (en) | Procurement, isolation, and cryopreservation of endometrial/menstrual cells | |
| CN104839146B (en) | Composition and application thereof, placenta preserve preparation and preparation method thereof | |
| CN114557337B (en) | Protein-free non-program freezing solution of umbilical cord mesenchymal stem cells and preparation method thereof | |
| KR20100084620A (en) | Cell composition for tissue regeneration | |
| CN107418930A (en) | A kind of preparation method purified with amplification human marrow mesenchymal stem cell | |
| CN109430252A (en) | A kind of stem cell cryopreserving liquid and preparation method thereof | |
| CN112481202A (en) | Method for serum-free separation culture of umbilical cord mesenchymal stem cells by using platelet lysate | |
| CN102146359A (en) | Method for extracting original mesenchymal stem cells from placenta and serum-free amplification | |
| US9206389B2 (en) | Culture for expanding stem cells ex-vivo | |
| CN112458047B (en) | Method for separating placenta mesenchymal stem cells and serum-free culture medium used by same | |
| US10400211B1 (en) | Cell composition for tissue regeneration | |
| CN104711308A (en) | Micromolecule substance for stimulating mesenchymal stem cells to secrete fibronectin | |
| CN116396930B (en) | Mesenchymal stem cell serum-free medium and application thereof | |
| Diana et al. | Regenerative Medicine Procedures for Aesthetic Physicians | |
| CN116584479A (en) | Cell refrigeration protective solution and preparation method and application thereof | |
| CN112608893A (en) | Separation and purification method of placenta mesenchymal stem cells | |
| CN113234662A (en) | Stem cell serum-free culture medium and preparation method and application thereof | |
| AU2011202711B2 (en) | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells | |
| CN115449503A (en) | Method for generating human liver parenchymal cells by in-vitro induction of IPS (IPS) cell differentiation | |
| NZ579705A (en) | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |